Citation Impact
Citing Papers
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8
2004 StandoutScience
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
Efficient production of [ n ]rotaxanes by using template-directed clipping reactions
2007 StandoutNobel
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
2006
Molecular imaging in drug development
2008 Standout
Adaptive walks with noisy fitness measurements
1995
Template-directed synthesis employing reversible imine bond formation
2007 StandoutNobel
Dynamic Covalent Chemistry
2002 StandoutNobel
A Common Core RNP Structure Shared between the Small Nucleoar Box C/D RNPs and the Spliceosomal U4 snRNP
2000 StandoutNobel
Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management
2010
Experimental and computational studies of the G[UUCG]C RNA tetraloop11Edited by I. Tinoco
2000
Epitope regions on U1 small nuclear RNA recognized by anti-U1RNA-specific autoantibodies.
1992
Cancer Statistics, 2006
2006 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics
2009
The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA
1997 StandoutNobel
Pitfalls in predicting tumor lysis syndrome
2006
TRIBE: Hijacking an RNA-Editing Enzyme to Identify Cell-Specific Targets of RNA-Binding Proteins
2016 StandoutNobel
Predicting ligand binding to proteins by affinity fingerprinting
1995
An Alternatively Spliced C. elegans ced-4 RNA Encodes a Novel Cell Death Inhibitor
1996 StandoutNobel
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
2007
Identification and Characterization of CPP32/Mch2 Homolog 1, a Novel Cysteine Protease Similar to CPP32
1996
Crystal structure at 1.92 Å resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin
1994 Nature
A Cell-Penetrating Scorpion Toxin Enables Mode-Specific Modulation of TRPA1 and Pain
2019 StandoutNobel
Conventional Therapy of Sjogren’s Syndrome
2007
Principles of adoptive T cell cancer therapy
2007
Immunity, Inflammation, and Cancer
2010 Standout
Identification and expansion of human colon-cancer-initiating cells
2006 StandoutNature
A DNA metalloenzyme with DNA ligase activity
1995 StandoutNatureNobel
Selection of high affinity RNA ligands to the bacteriophage R17 coat protein
1992
Cancer immunotherapy comes of age
2011 StandoutNature
In vitro selection of RNA aptamers specific for cyanocobalamin
1994 StandoutNobel
Cross-Intron Bridging Interactions in the Yeast Commitment Complex Are Conserved in Mammals
1997 StandoutNobel
In vitro evolution of a self-alkylatlng ribozyme
1995 StandoutNatureNobel
Synthesizing life
2001 StandoutNatureNobel
In vitro evolution of new ribozymes with polynucleotide kinase activity
1994 StandoutNatureNobel
HITS‐CLIP: panoramic views of protein–RNA regulation in living cells
2010
Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide
1996 StandoutNobel
The secondary structure and sequence optimization of an RNA ligase ribozyme
1995
The human U1 snRNP-Specific U1A protein inhibits polyadenylation of its own pre-mRNA
1993
Crystal structure of a hepatitis delta virus ribozyme
1998 StandoutNatureNobel
Structurally Complex and Highly Active RNA Ligases Derived from Random RNA Sequences
1995 StandoutScienceNobel
Inhibition of death receptor signals by cellular FLIP
1997 StandoutNature
In vitro evolution of nucleic acids
1994
Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice
1996 StandoutNature
Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies
2005
Adoptive Immunotherapy for Cancer or Viruses
2014
A molecular switch underlies a human telomerase disease
2002 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
The Tumor Lysis Syndrome
2011 Standout
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor.
1995 StandoutNobel
Roles of mutation and recombination in the evolution of protein thermodynamics
2002 StandoutNobel
An enhancer screen identifies a gene that encodes the yeast U1 snRNP A protein: implications for snRNP protein function in pre-mRNA splicing.
1993 StandoutNobel
Drug Discovery: A Historical Perspective
2000 StandoutScience
RNA RECOGNITION BY RNP PROTEINS DURING RNA PROCESSING
1998
A novel human protease similar to the interleukin-1 beta converting enzyme induces apoptosis in transfected cells.
1995
Informational Complexity and Functional Activity of RNA Structures
2004 StandoutNobel
Sequence-specific RNA Recognition by the Xenopus Y-box Proteins
1995
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
2014
A complex secondary structure in U1A pre-mRNA that binds two molecules of U1A protein is required for regulation of polyadenylation.
1993
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Complete, 12-subunit RNA polymerase II at 4.1-Å resolution: Implications for the initiation of transcription
2003 StandoutNobel
In Situ Selection of Lead Compounds by Click Chemistry: Target-Guided Optimization of Acetylcholinesterase Inhibitors
2005 StandoutNobel
Direct interaction of the U1 snRNP-A protein with the upstream efficiency element of the SV40 late polyadenylation signal.
1994
Catalytic Asymmetric Transacetalization
2010 StandoutNobel
Immune Therapy for Cancer
2008
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Structural and Kinetic Characterization of an Acyl Transferase Ribozyme
1998 StandoutNobel
Virtual combinatorial libraries: Dynamic generation of molecular and supramolecular diversity by self-assembly
1997 Nobel
Conserved Structures and Diversity of Functions of RNA-Binding Proteins
1994 StandoutScience
Direct Catalytic Asymmetric Synthesis of Cyclic Aminals from Aldehydes
2008 StandoutNobel
Caspases: Enemies Within
1998 StandoutScience
RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing.
1994
Interleukin-1 beta converting enzyme requires oligomerization for activity of processed forms in vivo.
1995
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease
2006 StandoutNatureNobel
Works of Donald E. Tsai being referenced
U1-snRNP-A protein selects a ten nucleotide consensus sequence from a degenerate RNA pool presented in various structural contexts
1991
Exploring molecular diversity with combinatorial shape libraries
1994
A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein–Barr virus
2006
Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma
2003
A predictive model for the detection of tumor lysis syndrome during AML induction therapy
2006
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation
2006
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
2005
A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
2003
In vitro selection of an RNA epitope immunologically cross-reactive with a peptide.
1992
In vitro selection of RNA epitopes using autoimmune patient serum
1993
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
2003
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma
2007